RT Journal Article
T1 Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
A1 Perez-Belmonte, Luis M
A1 Sanz-Canovas, Jaime
A1 Garcia-de-Lucas, Maria D
A1 Ricci, Michele
A1 Aviles-Bueno, Beatriz
A1 Cobos-Palacios, Lidia
A1 Perez-Velasco, Miguel A
A1 Lopez-Sampalo, Almudena
A1 Bernal-Lopez, M Rosa
A1 Jansen-Chaparro, Sergio
A1 Miramontes-Gonzalez, Jose P
A1 Gomez-Huelgas, Ricardo
K1 Health status
K1 Heart failure
K1 Obesity
K1 Semaglutide
K1 Type 2 diabetes
AB The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.
PB Frontiers Research Foundation
SN 1664-2392
YR 2022
FD 2022-06-24
LK http://hdl.handle.net/10668/20560
UL http://hdl.handle.net/10668/20560
LA en
NO Pérez-Belmonte LM, Sanz-Cánovas J, García de Lucas MD, Ricci M, Avilés-Bueno B, Cobos-Palacios L, et al. Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Front Endocrinol (Lausanne). 2022 Jun 24;13:851035
DS RISalud
RD Apr 9, 2025